- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Global Clinical Trial and Commercialization for Development of Next-generation Long-acting Glucagon (HM15136 ) for Congenital Hyperinsulinism (CHI) | ||||||
| Recombinant Protein | Congenital hyperinsulinism | glucagon | Phase 2 | Hanmi Pharm. Co., Ltd. | HN21C0601 | ||